CD52 and neoplasm: direct targeting MAbs; comprised of conventional antibodies that target tumor cells by direct binding to either lineage-specific antigens (such as CD20 or CD52), tumor neoantigens (e.g. glycans) or oncogenic biomarkers [e.g. epidermal growth factor receptor, EGFR (29)]; and